Last reviewed · How we verify
NCT05963061
Chronic Myeloid Leukemia (CML) Real-Life Database
trial in Chronic Myeloid Leukemia (CML) in 3,500 participants. Currently enrolling.
16 April 2034
Quick facts
| Lead sponsor | University Hospital, Clermont-Ferrand |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 3,500 |
| Start date | 16 April 2014 |
| Primary completion | 16 April 2034 |
| Estimated completion | 16 April 2034 |
| Sites | 14 locations across France |
Conditions studied
- Chronic Myeloid Leukemia (CML) — all drugs for Chronic Myeloid Leukemia (CML) →
Sponsor
University Hospital, Clermont-Ferrand
Who can join
Eligibility, any sex, with Chronic Myeloid Leukemia (CML). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Establish the largest possible real-life cohort collecting long-term follow-up of a maximum number of CML patients in order to carry out observational studies: epidemiological, identification of subgroups according to their response to treatment, evaluation of new molecules in real life, therapeutic discontinuations, impact of the evolution of recommendations, etc.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific tools.
Moinard S, Lebecque B, Lachaise T, Johnson-Ansah H, et al · · 2025 · PMID 40750677 · DOI 10.1038/s41375-025-02703-6
Verify or expand the search:
- PubMed search for NCT05963061
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Myeloid Leukemia (CML)
Currently open trials in the same condition.
- NCT07165535 — Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology Network · recruiting
- NCT06514534 — Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligi · Phase 2 · recruiting
- NCT05589896 — A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantat · Phase 1, PHASE2 · recruiting
- NCT03849651 — TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-ce · Phase 2 · active not recruiting
- NCT03481868 — EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors · NA · recruiting
Other University Hospital, Clermont-Ferrand trials
Trials by the same sponsor.
- NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
- NCT07476768 — PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot Study · NA · not yet recruiting
- NCT07439146 — Risk of Pneumonia in Intubated Patients in Emergency Situations · not yet recruiting
- NCT07427537 — Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients · NA · recruiting
- NCT07330856 — Evaluation of Treatments for Dry or Productive Cough · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05963061 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Clermont-Ferrand
- Last refreshed: 9 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05963061.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing